Logo
Lumifil Max with Lidocaine (1 x 1ml)

Lumifil Max with Lidocaine (1 x 1ml)

LUMIFIL

Dermal filler
  • Class III CE Marked hyaluronic acid dermal filler within the EU/EEA for injectable aesthetic use.
  • Manufactured under an ISO 13485 Compliant quality management system by BNC Korea, with processes to minimise residual cross Linker and ensure high purity.
  • Product labelling includes CE mark, device classification, lot/expiry, storage instructions and manufacturer details, in line with medical device regulations.
  • Distributed on a professional Only basis to licensed medical and aesthetic practitioners, consistent with regulatory and industry standards for injectable medical devices.
High-density hyaluronic acid dermal filler for deep facial augmentation and contouring

Description

Lumifil Max with Lidocaine is a premium, ultra-high purity cross-linked hyaluronic acid dermal filler supplied as a 1 ml pre-filled syringe. It is the thickest and longest-lasting formulation in the Lumifil range, specifically engineered for subcutaneous (Sub-Q) and deep-dermal augmentation. Lumifil Max is indicated for structural facial contouring and deep wrinkle correction, including non-surgical rhinoplasty and augmentation of the cheeks, jawline and chin. Developed using high molecular weight HA (around 2,500,000 Da) and patented particle technology, the filler offers high viscoelasticity, low phase angle and a dense, elastic texture that provides strong lifting capacity, robust projection and long-lasting results with reduced migration. The inclusion of 0.3% lidocaine improves patient comfort during injection. Typical duration of effect is quoted at approximately 9–15 months (and up to 12–18 months by some distributors), depending on treatment area, technique and individual factors.

Bnefits

  • Thickest and most volumising formulation in the Lumifil range, ideal for deep structural augmentation.
  • High-viscosity, high-density HA gel designed for Sub-Q areas and deep wrinkles including nose, cheeks, jawline and chin.
  • High viscoelasticity provides strong lift and support, maintaining shape and projection over time.
  • Low phase angle rheology helps the product stay closer to the injection site, minimising unwanted migration.
  • Patented particle technology ensures uniform HA particle structure for smoother injection, easier moulding and predictable results.
  • Ultra-high molecular weight HA (around 2,500,000 Da) makes it one of the densest HA fillers on the market, contributing to prolonged volume.
  • Contains 0.3% lidocaine to reduce procedure pain and improve patient comfort.
  • Ultra-high purity HA with low residual cross-linker (BDDE), in line with modern safety and quality expectations.
  • Effective for long-lasting contouring and volume restoration, typically around 9–15 months, sometimes reported up to 18 months depending on patient and indication.
  • Suitable for high-definition facial balancing and non-surgical rhinoplasty in experienced hands.

Indications

  • Deep tissue augmentation in Sub-Q planes of the face.
  • Non-surgical rhinoplasty (nose reshaping and projection).
  • Cheek enhancement and mid-face volumisation.
  • Jawline contouring and definition.
  • Chin augmentation and projection.
  • Treatment of deep and pronounced wrinkles and folds, including nasolabial folds and marionette lines, where a thick supportive filler is appropriate.
  • Restoration of significant age-related or structural volume loss in facial areas requiring strong lift and support.

Composition

  • Cross-linked sodium hyaluronate (hyaluronic acid) 20 mg/ml (non-animal sourced, produced by bacterial fermentation).
  • Lidocaine hydrochloride 3 mg/ml (0.3%) for local anaesthesia and reduced injection discomfort.
  • Phosphate-buffered saline (PBS) as physiological carrier solution.
  • Sterile water for injection and standard excipients as detailed in the official Instructions for Use.

Formulation

  • Monophasic, high-density cross-linked hyaluronic acid gel with lidocaine.
  • High molecular weight HA matrix (approx. 2,500,000 Da) processed using advanced cross-linking and patented particle technology for uniform structure and optimised rheology.
  • High viscoelasticity and cohesivity suitable for deep dermal and subcutaneous injection to create defined, long-lasting facial structures.
  • Designed specifically for deep contouring and high-lift applications rather than superficial fine-line correction.

Packaging

  • Standard unit: 1 x 1 ml pre-filled sterile syringe of Lumifil Max with Lidocaine.
  • Some wholesalers also offer outer cartons containing 10 x 1 ml boxes for clinic bulk purchasing.
  • Each box typically includes the pre-filled syringe and sterile disposable needles (often 25–27G, with exact gauge and quantity specified on the outer carton).
  • Packaging is CE-marked and labelled with product name, batch/lot number, expiry date, storage conditions, manufacturer and instructions for use.
  • Syringe and contents are intended for single-patient, single-use only.

Usage

  • For professional use only; must be administered by licensed healthcare professionals or trained aesthetic practitioners experienced in dermal filler injections.
  • Intended for mid-dermal to deep-dermal and subcutaneous injection, depending on the anatomical area and indication (e.g. nose, cheeks, jawline, chin, deep folds).
  • Perform a full consultation including medical history, indications, contraindications and informed consent prior to treatment.
  • Prepare the treatment area with appropriate cleansing and antiseptic techniques; maintain strict aseptic technique throughout the procedure (sterile gloves, needles, and equipment).
  • Use appropriate injection techniques such as deep bolus placement, linear threading, fanning or depot injections, tailored to area and desired contour; inject slowly with controlled pressure, avoiding intravascular injection.
  • In higher-risk vascular areas such as the nose and nasolabial region, aspirate according to clinic protocol and inject very cautiously using small volumes.
  • After injection, gently mould and contour the filler if necessary to achieve the desired shape, avoiding excessive manipulation that could cause displacement.
  • Provide patients with clear aftercare instructions, typically advising them to avoid makeup, alcohol, strenuous exercise, and extreme heat or cold (saunas, steam rooms, sunbeds) for at least 24 hours or as per clinic policy.
  • Schedule follow-up visits to assess results, manage any side effects and determine if minor touch-ups are required for optimal symmetry and contour.
  • Always follow the latest official Lumifil technical brochure and Instructions for Use for detailed guidance on indication-specific techniques, contraindications, and management of adverse events.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, lidocaine, other amide-type local anaesthetics or any excipient in the product.
  • Presence of active skin infection, inflammation or disease at or near the intended injection site (e.g. acne, dermatitis, herpes simplex/cold sores).
  • History of severe allergic reactions or anaphylaxis where elective injectable procedures pose increased risk.
  • Bleeding disorders or concurrent use of certain anticoagulant/antiplatelet therapies that significantly increase bleeding risk, unless carefully assessed by a suitably qualified clinician.
  • Autoimmune diseases, uncontrolled systemic illnesses or immunosuppressed states where dermal filler use may be contraindicated, unless risk–benefit evaluation supports treatment.
  • Pregnancy and breastfeeding, as elective cosmetic filler treatments are generally avoided due to lack of adequate safety data.
  • Previous permanent fillers or implants in the planned treatment area where there may be risk of interaction or tissue compromise, unless deemed safe by an experienced practitioner.
  • Any other contraindications, cautions or patient exclusions listed in the product’s official Instructions for Use or required by local regulations and professional guidelines.

Adverse Effects

  • Common, transient reactions at the injection site such as redness, swelling, tenderness, bruising, mild pain, itching, or small haematomas.
  • Localised lumps, nodules, irregularities or asymmetry, especially if injection depth, volume or placement is suboptimal or if filler is not adequately moulded.
  • Potential delayed-onset inflammatory reactions or granulomatous responses, as with other cross-linked HA fillers.
  • Infection at the injection site, including cellulitis or abscess, particularly if aseptic technique or post-care instructions are not followed.
  • Allergic or hypersensitivity reactions to hyaluronic acid, lidocaine or other components, which may present with swelling, erythema, pruritus or systemic symptoms.
  • Rare but serious complications including intravascular injection with vascular occlusion, tissue ischaemia or necrosis, and very rarely visual disturbance or blindness if filler enters vessels supplying the ocular region.
  • Practitioners should be trained to recognise and manage complications, including the use of hyaluronidase, appropriate massage, warm compresses and urgent referral when indicated.
  • Patients should be instructed to seek immediate medical attention if they experience severe or escalating pain, blanching or mottled skin, colour changes, visual symptoms, signs of infection or any other unexpected or concerning reactions.

Storage Conditions

  • Store in the original packaging at controlled room temperature, generally between 2°C and 25–30°C as indicated on the product carton.
  • Protect from direct sunlight and do not freeze; avoid exposure to excessive heat or cold that could compromise product integrity.
  • Keep out of reach of children and unauthorised persons; store in a secure clinical environment.
  • Do not use if the packaging is damaged, if the syringe or blister is compromised, if the gel appears discoloured or contains particulates, or if the product is past its expiry date.
  • Follow any additional storage and handling instructions detailed on the outer carton and in the Instructions for Use, including shelf-life and transport conditions.

Duration

Brand and distributor information commonly state that Lumifil Max with Lidocaine is effective for approximately 9\u201315 months, with some sources indicating up to 12\u201318 months in certain patients and treatment areas. Actual duration depends on treatment site, injection technique, volume used, patient metabolism and lifestyle, and may vary between individuals.

Onset

Structural augmentation and contouring results are visible immediately after injection. Final outcomes become more apparent once initial swelling and erythema resolve, typically within a few days to around two weeks.

Browse more Dermal filler

Top Treatments

Top Cities in the UK